MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with Multiple Sclerosis
23-Dec-2011 -
MorphoSys AG announced that a phase 1b clinical trial evaluating MOR103, a human monoclonal antibody to GM-CSF (granulocyte macrophage-colony stimulating factor), in patients with multiple sclerosis (MS) is now open for enrollment, thereby adding a second indication to the development program. A ...
monoclonal antibodies
MorphoSys
multiple sclerosis
+1